<DOC>
	<DOCNO>NCT02507336</DOCNO>
	<brief_summary>The study seek provide long-term follow-up and/or offer continue maintenance thalidomide ( THALOMID ) therapy patient enrol 20030165 . Patients follow withdrawal consent , death .</brief_summary>
	<brief_title>Long-Term Followup and/or Thalidomide Maintenance Therapy Patients Enrolled Clinical Trial 20030165</brief_title>
	<detailed_description>The study design provide long-term follow-up and/or offer continue maintenance thalidomide ( THALOMID® ) therapy patient enrol 20030165 . - Group A : Patients achieve complete response ( CR ) 20030165 continue receive maintenance Thalidomide . - Group B : Patients achieve complete response ( CR ) 20030165 , receive maintenance Thalidomide . - Group C : All patient enrol 20030165 expire experienced disease progression . Thalidomide ( THALOMID® ) administer per standard care guideline Group A ; compliance Risk Evaluation Mitigation Strategy ( REMS™ ) program requirement . Patients Group A , B C follow withdrawal consent , death . All patient Group C expire 20030165 also included analysis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Enrolled 20030165 clinical trial . 2 . Ability understand willingness sign write informed consent document . 1 . Patients discontinue 20030165 reason prior completion protocolspecified treatment ( e.g . withdrawal consent ) . 2 . Uncontrolled , intercurrent serious illness include limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , and/or cardiac arrhythmia likely judgment PI interfere clinical study requirement . 3 . Psychiatric illness/condition likely judgment PI limit compliance clinical study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mantle Cell Lymphoma ( MCL )</keyword>
	<keyword>Non-Hodgkin 's Lymphoma ( NHL )</keyword>
</DOC>